Company Encyclopedia
View More
name
DIRUI
300396.SZ
Dirui Industrial Co., Ltd. engages in the research and development, production, and sale of medical inspection products in the People's Republic of China. The company provides medical instruments and supporting test strip reagents. It also offers urine and biochemical analysis, chemiluminescence immunoassay, gynecological secretion analysis, blood cell analysis, coagulation analysis, and integrated laboratory products.
890.25 B
300396.SZMarket value -Rank by Market Cap -/-

Financial Score

06/12/2025 Update
D
Health Care EquipmentIndustry
Industry Ranking57/63
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-6.91%D
    • Profit Margin-26.98%E
    • Gross Margin27.84%C
  • Growth ScoreE
    • Revenue YoY-66.04%E
    • Net Profit YoY-158.96%E
    • Total Assets YoY-9.32%E
    • Net Assets YoY-9.57%D
  • Cash ScoreE
    • Cash Flow Margin-370.62%D
    • OCF YoY-66.04%E
  • Operating ScoreD
    • Turnover0.17D
  • Debt ScoreB
    • Gearing Ratio31.92%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    DIRUI Medical released its performance for the first three quarters, with a net loss attributable to the parent company of 87.254 million yuan

    According to the Zhitong Finance APP, DIRUI Medical released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 469 million yuan, a year-on-year decrease of 60.12%. The net loss attributable to shareholders of the listed company was 87.254 million yuan. The net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 93.9213 million yuan. The basic loss per share was 0.32 yuan

    Zhitong·
    SZ
    300396
    +0.15%
    Zhitong·
    SZ
    300396
    +0.15%

    DIRUI Medical: Song Qing, Qin Feng, Wang Xueming, and Lin Maoliang resign from the board of directors

    DIRUI Medical announced on the evening of July 22 that the company recently received a notice from its controlling shareholder, Shenzhen Huade Xinrun Equity Investment Enterprise, and a shareholder holding more than 5%, Guangdong Hengjian International Investment Co., Ltd. Due to changes in the positions of some directors at the shareholders and related units, and in conjunction with the actual work situation of the relevant personnel, Song Qing, Qin Feng, Wang Xueming, and Lin Maoliang will no longer serve as directors of the company. After resigning from their director positions, Song Qing, Qin Feng, and Lin Maoliang will not hold any positions in the company. Wang Xueming will continue to serve as a senior management personnel after resigning from the director position

    Zhitong·
    SZ
    300396
    +0.15%
    Zhitong·
    SZ
    300396
    +0.15%

    DIRUI Medical issued a profit warning, expecting a net loss of 22 million to 33 million yuan in the first half of the year

    According to the Zhitong Finance APP, DIRUI Medical has released its performance forecast for the first half of 2025, expecting a net loss attributable to shareholders of the listed company of 22 million to 33 million yuan, a shift from profit to loss compared to the same period last year. Reasons for the performance change: Due to the continuous impact of market factors and industry policies, the company's overall gross profit has declined. The international market remains relatively stable, while the domestic market's installation and reagent volume of the company's instrument products have not met expectations, resulting in a significant decrease in the company's net profit level

    Zhitong·
    SZ
    300396
    +0.15%
    Zhitong·
    SZ
    300396
    +0.15%

    The medical device sector saw a short-term surge, with JG Development hitting the daily limit

    The medical device sector saw a short-term surge, with JG Development hitting the limit up, BIOLIGHT rising over 10%, and Improve Medical, Tianyi Medical, DIRUI, Guanhao Biotech, and Chunli Medical also following suit

    Zhitong·
    SZ
    300238
    +0.14%
    SH
    688236
    +0.25%
    HK
    01858
    -1.28%
    Zhitong·
    SZ
    300238
    +0.14%
    SH
    688236
    +0.25%
    HK
    01858
    -1.28%

    DIRUI Medical: Hengjian International plans to reduce its holdings by no more than 3%

    DIRUI Medical announced that its shareholder Guangdong Hengjian International Investment Co., Ltd. plans to reduce its holdings by no more than 3%, specifically not exceeding 8,148,270 shares. The reduction will be carried out through bidding or block trading, with the implementation period being within 90 days after 15 trading days from the announcement date. The reduction through bidding will not exceed 2,710,630 shares, and the reduction through block trading will not exceed 5,437,640 shares

    Zhitong·
    SZ
    300396
    +0.15%
    Zhitong·
    SZ
    300396
    +0.15%
    © 2025 Longbridge｜Disclaimer